文献速递骨软组织肉瘤与黑色素瘤妇科肿瘤乳腺癌

晚期癌症青少年和年轻成人参与I期临床试验中的基因组分析作用

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.
PubMed 文献 · Eur J Cancer · 2018-03-31

该研究回顾性分析了2002至2016年在皇家马斯登医院药物开发单元治疗的219例15-39岁晚期实体瘤患者,评估胚系遗传评估和肿瘤分子分析的使用与影响。结果显示16%接受了胚系检测,其中22例携带致病性变异;21%接受了肿瘤检测,常见体细胞突变为TP53、PIK3CA、KRAS和MET。研究认为相当比例的患者具有可靶向的体细胞或胚系突变。

要点

  • 219例AYAs中,34例(16%)接受胚系检测,22例携带致病性变异。
  • 按现行标准,另32例(15%)仅凭个人肿瘤史即符合胚系检测条件。
  • 46例(21%)接受肿瘤检测,常见突变为TP53 13例(28%)、PIK3CA 8例(18%)、MET 5例(11%)、KRAS 4例(9%)。

核心结论

  • 相当比例的晚期癌症AYAs具有可靶向的体细胞或胚系突变。
  • 考虑家族风险因素并在适当时纳入胚系检测可补充肿瘤检测,优化患者管理并指导高危亲属管理。

研究设计与样本

  • 回顾性队列研究,纳入2002至2016年皇家马斯登医院药物开发单元治疗的219例15-39岁晚期实体瘤AYAs。
  • 通过病历回顾收集临床病理特征、临床评估及胚系和肿瘤基因检测数据。

主要发现

  • 常见肿瘤类型包括肉瘤41例(19%)、宫颈癌27例(12%)、乳腺癌25例(11%)、卵巢癌23例(11%)和结直肠癌21例(10%)。
  • 34例(16%)接受胚系检测,其中22例携带致病性变异。
  • 按现行检测标准,另32例(15%)仅凭个人肿瘤史即符合胚系检测条件。
  • 46例(21%)接受肿瘤检测,体细胞突变常见于TP53 13例(28%)、PIK3CA 8例(18%)、MET 5例(11%)和KRAS 4例(9%)。

临床怎么用

  • 对晚期癌症AYAs应考虑家族风险因素,适当时进行胚系检测以补充肿瘤检测。
  • 基因组分析结果可用于优化患者管理并指导高危亲属的管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Adolescents and young adults (AYAs) diagnosed with cancer between ages 15-39 years may harbour germline variants associated with cancer predisposition. Such variants represent putative therapeutic targets, as may somatic variants in the tumour. Germline and tumour molecular profiling is increasingly utilised to facilitate personalisation of cancer treatment in such individuals. AIM: Considering AYAs with advanced solid tumours managed in a specialist drug development unit (DDU), the aims of this study were to investigate the use and impact of: 1. Germline genetic assessment. 2. Tumour molecular profiling. METHODS: AYAs treated in the DDU at the Royal Marsden Hospital between 2002 and 2016 were identified from departmental databases. Data regarding clinicopathological features, clinical assessments and germline and tumour genetic testing were retrieved by chart review. RESULTS: The study cohort included 219 AYAs. Common cancer types included sarcoma (41, 19%); cervical (27, 12%); breast (25, 11%); ovarian (23, 11%) and colorectal (21, 10%) cancers. Germline testing was undertaken in 34 (16%) patients, 22 of whom carried a pathogenic variant. Using current testing criteria, an additional 32 (15%) would be eligible for germline testing based on their personal history of cancer alone. Tumour testing was undertaken in 46 (21%) individuals. Somatic mutations were commonly identified in TP53 13 (28%); PIK3CA (8, 18%); KRAS (4, 9%) and MET 5 (11%). DISCUSSION: A significant proportion of AYAs with advanced cancer have targetable somatic or germline mutations. Consideration of familial risk factors and inclusion of germline testing wherever appropriate can complement tumour testing to optimise patient management and inform management of at-risk relatives.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. McVeigh TP, Sundar R, Diamantis N, et al. The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials. Eur J Cancer. 2018. PMID: 29614442. doi:10.1016/j.ejca.2018.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。